Actuarial risk of isolated CNS involvement in Ewing's sarcoma following prophylactic cranial irradiation and intrathecal methotrexate.
Records of 154 patients with Ewing's sarcoma treated at the National Cancer Institute were reviewed to assess the incidence and risk of developing isolated central nervous system (CNS) Ewing's sarcoma. Sixty-two of the 154 patients had received CNS irradiation and intrathecal (i.t.) methotrexate as part of their initial therapy to prevent the occurrence of isolated CNS Ewing's sarcoma. The risk of developing isolated CNS Ewing's sarcoma was greatest within the first two years after diagnosis and was approximately 10%. The overall risk of CNS recurrence in the group of patients receiving CNS treatment was similar to the group receiving no therapy directed to the CNS. The occurrence of isolated CNS involvement was not prevented by the use of CNS irradiation and i.t. methotrexate. Because of a lack of efficacy to the CNS irradiation regimen, current treatment regimens do not include therapy directed to the CNS.
D000971:Antineoplastic Combined Chemotherapy Protocols; D001932:Brain Neoplasms / Q000453:epidemiology / Q000556:secondary*; D003131:Combined Modality Therapy; D006801:Humans; D007278:Injections, Spinal; D008727:Methotrexate / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D012306:Risk; D012512:Sarcoma, Ewing / Q000628:therapy*; D013997:Time Factors
D008727:Methotrexate